-Aceso Interactive, Inc., a leading provider of patient engagement and healthcare communication technology, is pleased to announce a strategic partnershi...
Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based therapeutic pla...
Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") and Shanghai ZJ Bio-Tech technology Co., Ltd. (hereinafter refer...
Recurrent respiratory papillomatosis (RRP) is a rare HPV-related disease of the respiratory tract with significant unmet need INO-3107 previously rece...
Collaboration will leverage AI-powered neural analysis and Compass' expertise in psychedelic drug development to advance new therapies for mental health ...
Discovery and development of the first systemic therapeutics to deliver self-antigens directly to the thymus to harness the body’s natural mechanis...
siRNA candidate EMP-012 in phase I for treatment of COPD EMP-012 targets a distinct inflammatory pathway with enhanced potency and longer dose int...
Reflects Catalent’s unparalleled service and best-in-class capabilities across the pharmaceutical, biotech and consumer health categories Rein...
Acquisition expands U.S. lab operations and accelerates innovation in non-invasive diagnostics for metabolic and liver diseases. Fibronostics, a global ...
Neurotronic, Inc., a developer of multi-organ denervation to treat complex cardiovascular and metabolic disease, announced that the first clinical outcom...
Financing designed to support Phase 2 Parkinson’s trial and accelerate Nugevia™ product line growth Jupiter Neurosciences, Inc , a clinical...
Protaryx Medical, an innovative medical device company developing disruptive access solutions for minimally invasive left-heart procedures, announced tha...
First U.S. Surgical Treatments with PFA Clamp for Patients with Atrial Fibrillation During Concomitant Surgical Procedure -Pulse Biosciences, ...
This approval is supported by data from the Phase III OASIS clinical trial program evaluating Lynkuet for the treatment of moderate to severe hot fla...
© 2025 Biopharma Boardroom. All Rights Reserved.
